Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases.
View/ Open
Date
2019-07-25Author
Zhang, C
Stockwell, SR
Elbanna, M
Ketteler, R
Freeman, J
Al-Lazikani, B
Eccles, S
De Haven Brandon, A
Raynaud, F
Hayes, A
Clarke, PA
Workman, P
Mittnacht, S
Type
Journal Article
Metadata
Show full item recordAbstract
Deregulation of cyclin-dependent kinases 4 and 6 (CDK4/6) is highly prevalent in cancer; yet, inhibitors against these kinases are currently used only in restricted tumour contexts. The extent to which cancers depend on CDK4/6 and the mechanisms that may undermine such dependency are poorly understood. Here, we report that signalling engaging the MET proto-oncogene receptor tyrosine kinase/focal adhesion kinase (FAK) axis leads to CDK4/6-independent CDK2 activation, involving as critical mechanistic events loss of the CDKI p21CIP1 and gain of its regulator, the ubiquitin ligase subunit SKP2. Combined inhibition of MET/FAK and CDK4/6 eliminates the proliferation capacity of cancer cells in culture, and enhances tumour growth inhibition in vivo. Activation of the MET/FAK axis is known to arise through cancer extrinsic and intrinsic cues. Our work predicts that such cues support cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases and identifies MET/FAK as a tractable route to broaden the utility of CDK4/6 inhibitor-based therapies in the clinic.
Collections
Subject
Animals
Humans
Mice
Cell Cycle
Cell Division
Proto-Oncogene Proteins c-met
Cyclin-Dependent Kinase 2
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Focal Adhesion Protein-Tyrosine Kinases
Heterografts
Biomarkers, Tumor
A549 Cells
Research team
Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
Computational Biology and Chemogenomics
Signal Transduction & Molecular Pharmacology
Language
eng
Date accepted
2019-05-13
License start date
2019-07-12
Citation
Oncogene, 2019, 38 (30), pp. 5905 - 5920
Publisher
NATURE PUBLISHING GROUP
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0
Related items
Showing items related by title, author, creator and subject.
-
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson, D; Griffin, MJ; Sludden, J; Drew, Y; Cresti, N; et al. (ELSEVIER SCI LTD, 2016-11-01)PURPOSE: We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, ... -
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker, SR; Cowley, GS; Wagner, S; Luo, F; Root, DE; et al. (AMER ASSOC CANCER RESEARCH, 2015-12-01)RAF and MEK inhibitors are effective in BRAF-mutant melanoma but not in BRAF-mutant colorectal cancer. To gain additional insights into this difference, we performed a genome-scale pooled shRNA enhancer screen in a ... -
Ubiquitin-Mediated Regulation of RIPK1 Kinase Activity Independent of IKK and MK2.
Annibaldi, A; Wicky John, S; Vanden Berghe, T; Swatek, KN; Ruan, J; et al. (CELL PRESS, 2018-02-15)Tumor necrosis factor (TNF) can drive inflammation, cell survival, and death. While ubiquitylation-, phosphorylation-, and nuclear factor κB (NF-κB)-dependent checkpoints suppress the cytotoxic potential of TNF, it remains ...